Trends and opportunities in the U.S. Hemophilia Treatment Market will drive growth owing to rising healthcare expenditure
The U.S. hemophilia treatment market offers therapeutic options for treating bleeding disorders like hemophilia A and B. Recombinant factor VIII and IX concentrates are commonly used to prevent and control bleeding in patients. Advances in injectable and extended half-life therapies have improved quality of life for many.
U.S. hemophilia treatment market size is expected to reach US$ 6.81 Bn by 2031, from US$ 4.21 Bn in 2023, exhibiting a compound annual growth rate (CAGR) of 6.2% during the forecast period.
U.S. Hemophilia Treatment Market https://www.coherentmi.com/ind....ustry-reports/us-hem
Like
Comment
Share
